Pharmaceutical Technology

MAY 30, 2023

Lecanemab leads the charge with projected sales of $4.67bn in 2028, 529% more than its closest competitor, Gammagard by Takeda. These drugs are set to make a combined $4.34bn in sales in 2028. Notably, American pharmaceutical mega-cap companies take the lead, with 80% representation among the top five drug launches.

Drugs 264

Drugs Sales Antibody Dermatology 264

The Pharma Data

NOVEMBER 8, 2020

9, 2020 /PRNewswire/ — Solid 9M business performance despite COVID-19 and generic Aczone challenges: Net Sales €613.8 Ilumetri ® sales grew +125% year-on-year and Seysara ® showed Net Sales performance improvement quarter-on-quarter following clinically relevant FDA label improvement. MM (-3.7%; +4.3%

Dermatology 52

Dermatology Sales Marketing Production 52

Pharmaceutical Technology

FEBRUARY 18, 2023

Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

Generic Pharmaceutical 100

Generic Pharmaceutical Dermatology Antibody Development 100

pharmaphorum

MAY 14, 2021

China’s Kintor Pharmaceutical has begun late-stage US clinical development of its potential COVID drug proxalutamide – but there is scepticism over the company’s claims about its research. Proxalutamide is not approved or available for sale and the Brazilian study has not been peer-reviewed or published.

Drug Trials 52

Drug Trials Trials Drugs Dermatology 52

The Pharma Data

MARCH 28, 2022

Dupixent peak sales ambition raised to more than €13 billion Chronic obstructive pulmonary disease 2023 pivotal readouts provide potential for additional Dupixent sales ambition upgrade 13 potential new medicines currently in the clinic to treat chronic inflammatory diseases, with 17 readouts expected by the end of 2024.

Medicine 52

Medicine Sales Clinical Development Development 52

XTalks

AUGUST 2, 2023

is a global pharmaceutical company, working across both developed and emerging markets. Most of the company’s revenue comes from the manufacture and sale of biopharmaceutical products. billion in pharmaceutical sales from 2021. Notably, sales from their COVID-19 drug Actemra (tocilizumab) dropped significantly by 22 percent.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

NOVEMBER 4, 2020

Juyou will be responsible for the overall clinical development and regulatory filings for Pliaglis with the National Medical Products Administration (the “NMPA”, formerly the China State Food and Drug Administration). . LAVAL, QC, Nov. million and US$1.8 Juyou Bio-Technology Co.,

Licensing 40

Licensing Licensing Dermatology Production 40